Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

November 29, 2024

Study Completion Date

December 13, 2024

Conditions

Health

Interventions

DRUG

UI009

inhale UI009 twice a day on Day 1 and Day 8.

DRUG

UIC202005

inhale UIC202005 twice a day on Day 1 and Day 8.

Trial Locations (1)

Chungnam National University Hospital, Daejeon

All Listed Sponsors

lead

Korea United Pharm. Inc.

INDUSTRY

NCT07110740 - Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects | Biotech Hunter | Biotech Hunter